AVITA Medical Highlights Data Presented By Researchers At BBA Annual Meeting Demonstrating Reduced Length Of Hospital Stay Among Burn Patients Treated With RECELL

AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a leading therapeutic acute wound care company delivering transformative solutions, today highlighted data presented by researchers at the British Burn Association (BBA) Annual Meeting demonstrating reduced length of hospital stay among burn patients treated with RECELL®. The session, titled The Clinical Impact of Skin Cell Suspension Autograft from a National Registry Perspective, represents the largest real-world analysis of skin cell suspension autograft (commercially known as RECELL) to date.

The patented RECELL technology uses a small sample of a patient's own skin to produce Spray-On Skin™ Cells, an autologous cell suspension that supports wound healing throughout the wound bed. Compared to traditional skin grafting, RECELL requires significantly less donor skin and offers a range of clinical benefits, including less pain at the donor site, faster healing, improved outcomes, and fewer procedures. These advantages contribute to shorter hospital stays and associated cost savings.